CA2468375A1
(en)
|
1993-07-19 |
1995-02-02 |
Angiotech Pharmaceuticals, Inc. |
Anti-angiogenic compositions, uses and methods
|
US20030203976A1
(en)
|
1993-07-19 |
2003-10-30 |
William L. Hunter |
Anti-angiogenic compositions and methods of use
|
KR100361933B1
(ko)
*
|
1993-09-08 |
2003-02-14 |
라 졸라 파마슈티칼 컴파니 |
화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
|
US5919455A
(en)
*
|
1993-10-27 |
1999-07-06 |
Enzon, Inc. |
Non-antigenic branched polymer conjugates
|
US5730990A
(en)
*
|
1994-06-24 |
1998-03-24 |
Enzon, Inc. |
Non-antigenic amine derived polymers and polymer conjugates
|
US7597886B2
(en)
*
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7820798B2
(en)
*
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US5932462A
(en)
*
|
1995-01-10 |
1999-08-03 |
Shearwater Polymers, Inc. |
Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
ZA963530B
(en)
*
|
1995-05-05 |
1996-11-05 |
Hoffmann La Roche |
Recombinant obese (ob) proteins
|
ES2093593T1
(es)
*
|
1995-05-05 |
1997-01-01 |
Hoffmann La Roche |
Proteinas obesas (ob) recombinantes.
|
US7048906B2
(en)
|
1995-05-17 |
2006-05-23 |
Cedars-Sinai Medical Center |
Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
|
US6833408B2
(en)
|
1995-12-18 |
2004-12-21 |
Cohesion Technologies, Inc. |
Methods for tissue repair using adhesive materials
|
ES2420106T3
(es)
|
1995-12-18 |
2013-08-22 |
Angiodevice International Gmbh |
Composiciones de polímeros reticulados y métodos para su uso
|
US7883693B2
(en)
|
1995-12-18 |
2011-02-08 |
Angiodevice International Gmbh |
Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
|
US6458889B1
(en)
|
1995-12-18 |
2002-10-01 |
Cohesion Technologies, Inc. |
Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US7357927B2
(en)
*
|
1996-03-12 |
2008-04-15 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
US6713061B1
(en)
|
1996-03-12 |
2004-03-30 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
US6441025B2
(en)
|
1996-03-12 |
2002-08-27 |
Pg-Txl Company, L.P. |
Water soluble paclitaxel derivatives
|
WO1997033904A1
(en)
|
1996-03-12 |
1997-09-18 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
BR9710646A
(pt)
*
|
1996-03-12 |
2000-01-11 |
Pg Txl Co Lp |
Pródrogas de paclitaxel solúveis em água.
|
US7964190B2
(en)
*
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
US6025324A
(en)
*
|
1996-05-15 |
2000-02-15 |
Hoffmann-La Roche Inc. |
Pegylated obese (ob) protein compositions
|
TW517067B
(en)
*
|
1996-05-31 |
2003-01-11 |
Hoffmann La Roche |
Interferon conjugates
|
EP0964702B1
(en)
*
|
1996-08-02 |
2006-10-04 |
Ortho-McNeil Pharmaceutical, Inc. |
Polypeptides having a single covalently bound n-terminal water-soluble polymer
|
US6214966B1
(en)
|
1996-09-26 |
2001-04-10 |
Shearwater Corporation |
Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
|
US8212004B2
(en)
*
|
1999-03-02 |
2012-07-03 |
Human Genome Sciences, Inc. |
Neutrokine-alpha fusion proteins
|
US6812327B1
(en)
*
|
1996-10-25 |
2004-11-02 |
Human Genome Sciences, Inc. |
Neutrokine-alpha polypeptides
|
US7122636B1
(en)
*
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
ES2215295T3
(es)
|
1997-02-21 |
2004-10-01 |
Genentech, Inc. |
Conjugados de polimeros y fragmentos de anticuerpo.
|
ATE352618T1
(de)
*
|
1997-03-17 |
2007-02-15 |
Human Genome Sciences Inc |
Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
|
US6872568B1
(en)
|
1997-03-17 |
2005-03-29 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5 antibodies
|
US20080248046A1
(en)
*
|
1997-03-17 |
2008-10-09 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
US20050233958A1
(en)
*
|
1997-03-17 |
2005-10-20 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
US20040136951A1
(en)
*
|
1997-03-17 |
2004-07-15 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
US5900402A
(en)
*
|
1997-05-29 |
1999-05-04 |
Enzon, Inc. |
Method of reducing side effects associated with administration of oxygen-carrying proteins
|
US6284246B1
(en)
*
|
1997-07-30 |
2001-09-04 |
The Procter & Gamble Co. |
Modified polypeptides with high activity and reduced allergenicity
|
CA2302834A1
(en)
*
|
1997-09-18 |
1999-03-25 |
F. Hoffmann-La Roche Ag |
Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c
|
WO1999029759A1
(en)
*
|
1997-12-12 |
1999-06-17 |
Macromed, Inc. |
Heterofunctionalized star-shaped poly(ethylene glycols) for protein modification
|
US6180095B1
(en)
|
1997-12-17 |
2001-01-30 |
Enzon, Inc. |
Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
|
JP4465109B2
(ja)
|
1997-12-17 |
2010-05-19 |
エンゾン ファーマシューティカルズ,インコーポレーテッド |
アミノ及びヒドロキシル含有生物活性剤のポリマープロドラッグ
|
US5965119A
(en)
*
|
1997-12-30 |
1999-10-12 |
Enzon, Inc. |
Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
|
US6624142B2
(en)
|
1997-12-30 |
2003-09-23 |
Enzon, Inc. |
Trimethyl lock based tetrapartate prodrugs
|
US7005504B2
(en)
*
|
1998-01-22 |
2006-02-28 |
Genentech, Inc. |
Antibody fragment-peg conjugates
|
US6458355B1
(en)
|
1998-01-22 |
2002-10-01 |
Genentech, Inc. |
Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
|
US6468532B1
(en)
|
1998-01-22 |
2002-10-22 |
Genentech, Inc. |
Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
|
US6066673A
(en)
*
|
1998-03-12 |
2000-05-23 |
The Procter & Gamble Company |
Enzyme inhibitors
|
US6942859B2
(en)
|
1998-03-13 |
2005-09-13 |
University Of Southern California |
Red blood cells covalently bound with polymers
|
US6312685B1
(en)
|
1998-03-13 |
2001-11-06 |
Timothy C. Fisher |
Red blood cells covalently bound with two different polyethylene glycol derivatives
|
US6153655A
(en)
*
|
1998-04-17 |
2000-11-28 |
Enzon, Inc. |
Terminally-branched polymeric linkers and polymeric conjugates containing the same
|
US6251382B1
(en)
|
1998-04-17 |
2001-06-26 |
Enzon, Inc. |
Biodegradable high molecular weight polymeric linkers and their conjugates
|
EP1087778B1
(en)
*
|
1998-06-08 |
2005-10-26 |
F. Hoffmann-La Roche Ag |
Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
|
US6214330B1
(en)
|
1998-07-13 |
2001-04-10 |
Enzon, Inc. |
Coumarin and related aromatic-based polymeric prodrugs
|
US20060188971A1
(en)
*
|
1998-08-06 |
2006-08-24 |
Duke University |
Urate oxidase
|
IL141221A0
(en)
|
1998-08-06 |
2002-03-10 |
Univ Duke |
Urate oxidase
|
DE69943205D1
(de)
|
1998-08-06 |
2011-03-31 |
Mountain View Pharmaceuticals |
Peg-uricase Konjugate und Verwendung davon
|
US6783965B1
(en)
*
|
2000-02-10 |
2004-08-31 |
Mountain View Pharmaceuticals, Inc. |
Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
|
AU766190B2
(en)
*
|
1998-10-16 |
2003-10-09 |
Biogen Idec Ma Inc. |
Interferon-beta fusion proteins and uses
|
IL142282A0
(en)
*
|
1998-10-16 |
2002-03-10 |
Biogen Inc |
Compositions containing polymer conjugates of interferon-beta-1a
|
US6458953B1
(en)
*
|
1998-12-09 |
2002-10-01 |
La Jolla Pharmaceutical Company |
Valency platform molecules comprising carbamate linkages
|
CA2362937C
(en)
*
|
1999-02-24 |
2011-03-22 |
The Uab Research Foundation |
Taxane derivatives for targeted therapy of cancer
|
EP2357192A1
(en)
|
1999-02-26 |
2011-08-17 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
US6852696B2
(en)
|
1999-03-26 |
2005-02-08 |
The University Of Texas System |
Inhibitors of glycosaminoglycans
|
US7169889B1
(en)
|
1999-06-19 |
2007-01-30 |
Biocon Limited |
Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
|
PE20010288A1
(es)
|
1999-07-02 |
2001-03-07 |
Hoffmann La Roche |
Derivados de eritropoyetina
|
CZ299516B6
(cs)
*
|
1999-07-02 |
2008-08-20 |
F. Hoffmann-La Roche Ag |
Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
|
WO2001016210A1
(en)
*
|
1999-08-27 |
2001-03-08 |
Cohesion Technologies, Inc. |
Compositions that form interpenetrating polymer networks for use as high strength medical sealants
|
CN1111166C
(zh)
*
|
1999-09-10 |
2003-06-11 |
云南汉德生物技术有限公司 |
水溶性三尖杉磷碱聚氨基酸酯或其盐,含它们的药物组合物及其医药用途
|
US6713454B1
(en)
*
|
1999-09-13 |
2004-03-30 |
Nobex Corporation |
Prodrugs of etoposide and etoposide analogs
|
US6376470B1
(en)
|
1999-09-23 |
2002-04-23 |
Enzon, Inc. |
Polymer conjugates of ara-C and ara-C derivatives
|
JP4776843B2
(ja)
|
1999-10-01 |
2011-09-21 |
イムノゲン インコーポレーティッド |
免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
|
CA2395254C
(en)
*
|
1999-12-24 |
2010-05-11 |
Kyowa Hakko Kogyo Co., Ltd. |
Branched polyalkylene glycols
|
MXPA02006795A
(es)
|
2000-01-10 |
2005-04-19 |
Maxygen Holdings Ltd |
Conjugados g-csf.
|
RU2278123C2
(ru)
|
2000-02-11 |
2006-06-20 |
Максиджен Холдингз Лтд. |
Молекулы, подобные фактору vii или viia
|
US6756037B2
(en)
|
2000-03-31 |
2004-06-29 |
Enzon, Inc. |
Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
|
US6777387B2
(en)
|
2000-03-31 |
2004-08-17 |
Enzon Pharmaceuticals, Inc. |
Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
|
DE60122500T2
(de)
*
|
2000-04-04 |
2007-05-03 |
Bioartificial Gel Technologies Inc., Montreal |
Verfahren zur herstellung von proteinhaltigen hydrogelen
|
AU2001266557A1
(en)
|
2000-04-12 |
2001-10-23 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
CN1309416C
(zh)
|
2000-05-15 |
2007-04-11 |
霍夫曼-拉罗奇有限公司 |
新的药物组合物
|
SG98393A1
(en)
|
2000-05-19 |
2003-09-19 |
Inst Materials Research & Eng |
Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
|
US7259146B2
(en)
|
2000-05-26 |
2007-08-21 |
Ortho-Mcneil Pharmaceutical, Inc. |
Neuroprotective peptides
|
EP1292337A2
(en)
|
2000-06-08 |
2003-03-19 |
La Jolla Pharmaceutical |
Multivalent platform molecules comprising high molecular weight polyethylene oxide
|
AU2001282856A1
(en)
|
2000-06-15 |
2001-12-24 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
US7879328B2
(en)
*
|
2000-06-16 |
2011-02-01 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator
|
KR20060088905A
(ko)
*
|
2000-06-16 |
2006-08-07 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
면역특이적으로 BLyS에 결합하는 항체
|
CN1460023A
(zh)
*
|
2000-07-12 |
2003-12-03 |
格莱风治疗公司 |
聚合物修饰的生物活性合成趋化因子及其生产方法和用途
|
KR100396983B1
(ko)
*
|
2000-07-29 |
2003-09-02 |
이강춘 |
고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
|
WO2002016412A2
(en)
|
2000-08-18 |
2002-02-28 |
Dyax Corp. |
Binding polypeptides for b lymphocyte stimulator protein (blys)
|
AU2001288301A1
(en)
*
|
2000-08-18 |
2002-03-04 |
Human Genome Sciences, Inc. |
Binding polypeptides and methods based thereon
|
US7118737B2
(en)
|
2000-09-08 |
2006-10-10 |
Amylin Pharmaceuticals, Inc. |
Polymer-modified synthetic proteins
|
EP1315511A4
(en)
*
|
2000-09-08 |
2005-10-19 |
Gryphon Therapeutics Inc |
SYNTHESIS PROTEINS STIMULATING ERYTHROPOYSIS
|
EP1324779B1
(en)
*
|
2000-09-29 |
2011-07-20 |
Schering Corporation |
Pegylated interleukin-10
|
US20020065397A1
(en)
|
2000-10-12 |
2002-05-30 |
Joseph Roberts |
Protecting therapeutic compositions from host-mediated inactivation
|
ES2320101T3
(es)
|
2000-10-16 |
2009-05-19 |
Chugai Seiyaku Kabushiki Kaisha |
Eritropoyetina conjugada con mono-peg.
|
US20030228309A1
(en)
*
|
2000-11-08 |
2003-12-11 |
Theodora Salcedo |
Antibodies that immunospecifically bind to TRAIL receptors
|
US20060062786A1
(en)
*
|
2000-11-08 |
2006-03-23 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to TRAIL receptors
|
US7053150B2
(en)
|
2000-12-18 |
2006-05-30 |
Nektar Therapeutics Al, Corporation |
Segmented polymers and their conjugates
|
WO2002051428A1
(fr)
*
|
2000-12-25 |
2002-07-04 |
Shiseido Company, Ltd. |
Composition de parfum stimulant le systeme sympathique
|
JP4152187B2
(ja)
|
2001-01-30 |
2008-09-17 |
協和醗酵工業株式会社 |
分岐型ポリアルキレングリコール類
|
ES2284858T3
(es)
|
2001-02-02 |
2007-11-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
Tratamiento de disfuncion neurologica que comprende sulfamatos de fructopiranosa y eritropoyetina.
|
DE60223499T2
(de)
*
|
2001-02-20 |
2008-10-16 |
Enzon, Inc. |
Terminal verzweigte, polymere linker und diese enthaltende polymere konjugate
|
JP2004534523A
(ja)
|
2001-02-27 |
2004-11-18 |
マキシゲン・エイピーエス |
新規なインターフェロンβ様分子
|
AU2002258749A1
(en)
*
|
2001-03-21 |
2002-10-08 |
The University Of Texas System |
Inhibitors of glycosaminoglycans
|
US7348003B2
(en)
|
2001-05-25 |
2008-03-25 |
Human Genome Sciences, Inc. |
Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
|
US20090226429A1
(en)
*
|
2001-05-25 |
2009-09-10 |
Human Genome Sciences, Inc. |
Antibodies That Immunospecifically Bind to TRAIL Receptors
|
US7361341B2
(en)
*
|
2001-05-25 |
2008-04-22 |
Human Genome Sciences, Inc. |
Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
|
US20050214209A1
(en)
*
|
2001-05-25 |
2005-09-29 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to TRAIL receptors
|
CN100594935C
(zh)
*
|
2001-05-25 |
2010-03-24 |
人体基因组科学有限公司 |
免疫特异性结合trail受体的抗体
|
US6713452B2
(en)
|
2001-06-04 |
2004-03-30 |
Nobex Corporation |
Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US7713932B2
(en)
|
2001-06-04 |
2010-05-11 |
Biocon Limited |
Calcitonin drug-oligomer conjugates, and uses thereof
|
US6828297B2
(en)
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6858580B2
(en)
|
2001-06-04 |
2005-02-22 |
Nobex Corporation |
Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6828305B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6835802B2
(en)
|
2001-06-04 |
2004-12-28 |
Nobex Corporation |
Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
|
US20040077835A1
(en)
*
|
2001-07-12 |
2004-04-22 |
Robin Offord |
Chemokine receptor modulators, production and use
|
CA2457876C
(en)
*
|
2001-08-22 |
2011-10-11 |
Bioartificial Gel Technologies Inc. |
Process for the preparation of activated polyethylene glycols
|
GB0121709D0
(en)
*
|
2001-09-07 |
2001-10-31 |
Imp College Innovations Ltd |
Food inhibition agent
|
DE60230818D1
(de)
|
2001-09-24 |
2009-02-26 |
Imp Innovations Ltd |
Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US8008252B2
(en)
|
2001-10-10 |
2011-08-30 |
Novo Nordisk A/S |
Factor VII: remodeling and glycoconjugation of Factor VII
|
WO2004099231A2
(en)
|
2003-04-09 |
2004-11-18 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
US7795210B2
(en)
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
WO2003040211A2
(en)
*
|
2001-11-07 |
2003-05-15 |
Nektar Therapeutics Al, Corporation |
Branched polymers and their conjugates
|
US6818613B2
(en)
|
2001-11-07 |
2004-11-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
Aqueous sustained-release formulations of proteins
|
US20030171285A1
(en)
*
|
2001-11-20 |
2003-09-11 |
Finn Rory F. |
Chemically-modified human growth hormone conjugates
|
WO2003045423A1
(en)
*
|
2001-11-28 |
2003-06-05 |
Ortho-Mcneil Pharmaceutical, Inc. |
Erythropoietin dosing regimen for treating anemia
|
EP1465925A4
(en)
*
|
2001-12-20 |
2006-02-08 |
Human Genome Sciences Inc |
"ANTIBODIES THAT IMMUNE SPECIFICALLY TO TRAIL RECEPTORS"
|
EP2990417A1
(en)
|
2001-12-21 |
2016-03-02 |
Human Genome Sciences, Inc. |
Albumin insulin fusion protein
|
US8058233B2
(en)
*
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
CA2472882A1
(en)
|
2002-01-10 |
2003-07-17 |
Imperial College Innovations Ltd |
Use of pyy and glp-1, or an agonist thereof, for the modification of feeding behaviour
|
US7144978B2
(en)
|
2002-01-15 |
2006-12-05 |
Pan Asia Bio Co., Ltd. |
Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
|
AU2003218045A1
(en)
*
|
2002-03-11 |
2003-09-29 |
Ortho Mcneil Pharmaceutical, Inc |
Methods for shp1 mediated neuroprotection
|
EP1496076B1
(en)
*
|
2002-03-13 |
2007-07-25 |
Beijing Jiankai Technology Co., Ltd. |
Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound
|
EP1490402A4
(en)
*
|
2002-03-20 |
2007-05-02 |
Biopolymed Inc |
PREPARATION OF CYSTEINREST STOCHIOMETRIC WITH BIOKOMPATIBLE POLYMER CONJUGATED G-CSF
|
AU2003218456A1
(en)
*
|
2002-04-01 |
2003-10-20 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to gmad
|
ITMI20020951A1
(it)
*
|
2002-05-06 |
2003-11-06 |
Univ Degli Studi Trieste |
Derivati multifunzionali del polietilenglicole loro preparazione ed impiego
|
ES2370710T3
(es)
*
|
2002-05-28 |
2011-12-22 |
Ucb Pharma, S.A. |
ISÓMERO POSICIONAL DE PEG DE UN ANTICUERPO ANTI-TNFalfa (CDP870).
|
MXPA04012496A
(es)
|
2002-06-21 |
2005-09-12 |
Novo Nordisk Healthcare Ag |
Glicoformos del factor vii pegilados.
|
ES2363205T3
(es)
|
2002-06-21 |
2011-07-26 |
Novo Nordisk Health Care Ag |
Glicoformas del factor vii pegilado.
|
US20060094643A1
(en)
*
|
2002-07-03 |
2006-05-04 |
Yuri Svirkin |
Compositions of hyaluronic acid and methods of use
|
CN100519643C
(zh)
|
2002-07-19 |
2009-07-29 |
奥默罗斯公司 |
可生物降解的三嵌段共聚物,它们的合成方法和从它制得的水凝胶和生物材料
|
US7122189B2
(en)
|
2002-08-13 |
2006-10-17 |
Enzon, Inc. |
Releasable polymeric conjugates based on aliphatic biodegradable linkers
|
US7413738B2
(en)
*
|
2002-08-13 |
2008-08-19 |
Enzon Pharmaceuticals, Inc. |
Releasable polymeric conjugates based on biodegradable linkers
|
US7087229B2
(en)
*
|
2003-05-30 |
2006-08-08 |
Enzon Pharmaceuticals, Inc. |
Releasable polymeric conjugates based on aliphatic biodegradable linkers
|
AU2003265361A1
(en)
*
|
2002-08-28 |
2004-03-19 |
Pharmacia Corporation |
Stable ph optimized formulation of a modified antibody
|
WO2004019860A2
(en)
*
|
2002-08-28 |
2004-03-11 |
Pharmacia Corporation |
Formulations of modified antibodies and methods of making the same
|
US7459435B2
(en)
|
2002-08-29 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
US20040062748A1
(en)
|
2002-09-30 |
2004-04-01 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
US8129330B2
(en)
*
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
TWI281864B
(en)
*
|
2002-11-20 |
2007-06-01 |
Pharmacia Corp |
N-terminally monopegylated human growth hormone conjugates and process for their preparation
|
US7459436B2
(en)
|
2002-11-22 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
US9125880B2
(en)
*
|
2002-12-26 |
2015-09-08 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates of interferon-beta with enhanced biological potency
|
BR0317752A
(pt)
*
|
2002-12-26 |
2005-11-22 |
Mountain View Pharmaceuticals |
Conjugados poliméricos de citocinas, quimiocinas, fatores do crescimento, hormÈnios polipeptìdicos e seus antagonistas com atividade de ligação a receptores conservada
|
AU2003303595A1
(en)
*
|
2002-12-30 |
2004-07-29 |
Gryphon Therapeutics, Inc. |
Water-soluble thioester and selenoester compounds and methods for making and using the same
|
AU2003300076C1
(en)
*
|
2002-12-30 |
2010-03-04 |
Angiotech International Ag |
Drug delivery from rapid gelling polymer composition
|
JP2006519766A
(ja)
*
|
2002-12-30 |
2006-08-31 |
アンジオテック インターナショナル アクツィエン ゲゼルシャフト |
組織反応性化合物および組成物、ならびにそれらの使用法
|
GB0300571D0
(en)
*
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
US20090123367A1
(en)
*
|
2003-03-05 |
2009-05-14 |
Delfmems |
Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
|
US7871607B2
(en)
*
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
PL2163643T3
(pl)
*
|
2003-03-05 |
2015-06-30 |
Halozyme Inc |
Rozpuszczalna glikoproteina o aktywności hialuronidazy (sHASEGP), sposób jej wytwarzania, zastosowania oraz zawierające ją kompozycje farmaceutyczne
|
JP2006523211A
(ja)
|
2003-03-14 |
2006-10-12 |
ネオス テクノロジーズ インコーポレイテッド |
分岐水溶性ポリマーとその複合物
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
ES2340494T3
(es)
|
2003-04-15 |
2010-06-04 |
Glaxosmithkline Llc |
Mutantes de sustitucion de il-18 humana y sus conjugados.
|
BRPI0410164A
(pt)
*
|
2003-05-09 |
2006-05-16 |
Neose Technologies Inc |
composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano
|
US20070172446A1
(en)
|
2003-05-16 |
2007-07-26 |
Intermune, Inc. |
Synthetic chemokine receptor ligands and methods of use thereof
|
US7947261B2
(en)
|
2003-05-23 |
2011-05-24 |
Nektar Therapeutics |
Conjugates formed from polymer derivatives having particular atom arrangements
|
WO2005000360A2
(en)
*
|
2003-05-23 |
2005-01-06 |
Nektar Therapeutics Al, Corporation |
Peg derivatives having an amidocarbonate linkage
|
US9005625B2
(en)
|
2003-07-25 |
2015-04-14 |
Novo Nordisk A/S |
Antibody toxin conjugates
|
WO2005023294A2
(en)
|
2003-09-05 |
2005-03-17 |
The General Hospital Corporation |
Polyacetal drug conjugates as release system
|
EP1525890A1
(en)
|
2003-10-02 |
2005-04-27 |
Complex Biosystems GmbH |
Protein-Proteophore complexes
|
EP1675620B1
(en)
*
|
2003-10-09 |
2019-05-08 |
Ambrx, Inc. |
Polymer derivatives
|
ATE481420T1
(de)
|
2003-10-10 |
2010-10-15 |
Novo Nordisk As |
Il-21-derivate
|
CN102020697B
(zh)
|
2003-10-14 |
2014-10-29 |
F·霍夫曼-罗须公司 |
作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺
|
EP2641611A3
(en)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Combination therapy
|
US7407973B2
(en)
*
|
2003-10-24 |
2008-08-05 |
Intermune, Inc. |
Use of pirfenidone in therapeutic regimens
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
CA2547140A1
(en)
*
|
2003-11-24 |
2005-06-09 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
US20060040856A1
(en)
*
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
US7956032B2
(en)
|
2003-12-03 |
2011-06-07 |
Novo Nordisk A/S |
Glycopegylated granulocyte colony stimulating factor
|
US20080015142A1
(en)
*
|
2003-12-03 |
2008-01-17 |
Defrees Shawn |
Glycopegylated Follicle Stimulating Hormone
|
PT1694363E
(pt)
*
|
2003-12-16 |
2014-02-20 |
Nektar Therapeutics |
Composições monodispersas de naloxol peguilado
|
US20060182692A1
(en)
*
|
2003-12-16 |
2006-08-17 |
Fishburn C S |
Chemically modified small molecules
|
DK1696947T3
(da)
|
2003-12-19 |
2014-03-17 |
Hoffmann La Roche |
Anvendelse af erythropoietin i behandlingen af forstyrrelser af jernfordelingen i kronisk inflammatorisk intestinale sygdomme
|
US8361961B2
(en)
|
2004-01-08 |
2013-01-29 |
Biogenerix Ag |
O-linked glycosylation of peptides
|
MXPA06008507A
(es)
|
2004-02-02 |
2008-02-13 |
Ambrx Inc |
Cuatro polipeptidos en haz helicoidal humanos modificados y sus usos.
|
PL1729795T3
(pl)
|
2004-02-09 |
2016-08-31 |
Human Genome Sciences Inc |
Białka fuzyjne albuminy
|
US6887952B1
(en)
*
|
2004-02-12 |
2005-05-03 |
Biosite, Inc. |
N-aryl-carbamic acid ester-derived and valeric acid ester-derived cross-linkers and conjugates, and methods for their synthesis and use
|
US7351787B2
(en)
|
2004-03-05 |
2008-04-01 |
Bioartificial Gel Technologies, Inc. |
Process for the preparation of activated polyethylene glycols
|
US20050238628A1
(en)
*
|
2004-04-08 |
2005-10-27 |
Blau Carl A |
Methods for treating cancer
|
US8067031B2
(en)
|
2004-04-28 |
2011-11-29 |
Angiodevice International Gmbh |
Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
|
WO2005108463A2
(en)
*
|
2004-05-03 |
2005-11-17 |
Nektar Therapeutics Al, Corporation |
Branched polyethylen glycol derivates comprising an acetal or ketal branching point
|
KR101699142B1
(ko)
*
|
2004-06-18 |
2017-01-23 |
암브룩스, 인코포레이티드 |
신규 항원-결합 폴리펩티드 및 이의 용도
|
WO2006010143A2
(en)
|
2004-07-13 |
2006-01-26 |
Neose Technologies, Inc. |
Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
|
UA91512C2
(ru)
|
2004-07-19 |
2010-08-10 |
Биокон Лимитед |
Коньюгати олигомеров инсулина, их композиция (варианты) и применение
|
EP1771573A4
(en)
*
|
2004-07-21 |
2009-02-18 |
Ambrx Inc |
BIOSYNTHETIC POLYPEPTIDES OBTAINED FROM NON-NATURALLY CITED AMINO ACIDS
|
WO2006020372A2
(en)
*
|
2004-07-23 |
2006-02-23 |
Neose Technologies, Inc. |
Enzymatic modification of glycopeptides
|
US7772182B2
(en)
*
|
2004-08-05 |
2010-08-10 |
Alza Corporation |
Stable suspension formulations of erythropoietin receptor agonists
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
EP1789074A4
(en)
*
|
2004-08-09 |
2009-08-12 |
Alios Biopharma Inc |
PROTEASE-RESISTANT HYPERGLYCOSYL SYNTHETIC POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME
|
EP1794588A2
(en)
*
|
2004-09-09 |
2007-06-13 |
Biosite Incorporated |
Methods and compositions for measuring canine bnp and uses thereof
|
EP1799249A2
(en)
|
2004-09-10 |
2007-06-27 |
Neose Technologies, Inc. |
Glycopegylated interferon alpha
|
WO2006034128A2
(en)
|
2004-09-17 |
2006-03-30 |
Angiotech Biomaterials Corporation |
Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use
|
US8790632B2
(en)
*
|
2004-10-07 |
2014-07-29 |
Actamax Surgical Materials, Llc |
Polymer-based tissue-adhesive form medical use
|
WO2006042161A2
(en)
|
2004-10-07 |
2006-04-20 |
E.I. Dupont De Nemours And Company |
Polysaccharide-based polymer tissue adhesive for medical use
|
PL2586456T3
(pl)
|
2004-10-29 |
2016-07-29 |
Ratiopharm Gmbh |
Remodeling i glikopegilacja czynnika wzrostu fibroblastów (FGF)
|
EP2284191A3
(en)
|
2004-12-22 |
2011-07-20 |
Ambrx, Inc. |
Process for the preparation of hGH
|
NZ555308A
(en)
|
2004-12-22 |
2010-10-29 |
Ambrx Inc |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
NZ555386A
(en)
|
2004-12-22 |
2011-01-28 |
Ambrx Inc |
Formulations of human growth hormone comprising a non-naturally encoded amino acid
|
BRPI0519568C8
(pt)
*
|
2004-12-22 |
2022-06-14 |
Ambrx Inc |
Aminoacil-trna sintetase (rs), composições que compreendem a dita aminoacil-trna sintetase, célula de levedura, célula fúngica, célula não eucariótica, vetor que codifica uma rs, polinucleotídeo e ainda método para produzir um polipeptídeo em uma célula com um aminoácido selecionado em uma posição especificada
|
KR20070100299A
(ko)
*
|
2004-12-22 |
2007-10-10 |
암브룩스, 인코포레이티드 |
재조합 인간 성장 호르몬의 발현 및 정제 방법
|
EP2514757A3
(en)
|
2005-01-10 |
2014-03-05 |
ratiopharm GmbH |
Glycopegylated granulocyte colony stimulating factor
|
US7879979B2
(en)
*
|
2005-01-21 |
2011-02-01 |
Alere International |
Arginine analogs, and methods for their synthesis and use
|
US7365127B2
(en)
*
|
2005-02-04 |
2008-04-29 |
Enzon Pharmaceuticals, Inc. |
Process for the preparation of polymer conjugates
|
WO2006086617A2
(en)
*
|
2005-02-10 |
2006-08-17 |
Emory University |
Polyethylene oxide polymers including anti-inflammatory glycodendrons
|
US20090202619A1
(en)
*
|
2005-02-18 |
2009-08-13 |
The University Of Tokushima |
Polyoxyalkylene chain-containing lipid derivative and lipid film structure containing such derivative
|
WO2006088248A1
(ja)
|
2005-02-18 |
2006-08-24 |
Nof Corporation |
ポリオキシアルキレン誘導体
|
EP2314320A2
(en)
|
2005-04-05 |
2011-04-27 |
Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. |
Method for shielding functional sites or epitopes on proteins
|
EP1871795A4
(en)
|
2005-04-08 |
2010-03-31 |
Biogenerix Ag |
COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
|
US20080159976A1
(en)
*
|
2005-04-11 |
2008-07-03 |
Jacob Hartman |
Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
|
SI3321359T1
(sl)
|
2005-04-11 |
2021-07-30 |
Horizon Pharma Rheumatology Llc |
Variantne oblike urat oksidaze in uporaba le-teh
|
NZ562291A
(en)
|
2005-04-11 |
2010-02-26 |
Savient Pharmaceuticals Inc |
A variant form of urate oxidase and use thereof
|
US8148123B2
(en)
*
|
2005-04-11 |
2012-04-03 |
Savient Pharmaceuticals, Inc. |
Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
|
US8273339B2
(en)
|
2005-04-12 |
2012-09-25 |
Nektar Therapeutics |
Polymer-based compositions and conjugates of antimicrobial agents
|
US7833979B2
(en)
*
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
WO2006125452A1
(en)
*
|
2005-05-23 |
2006-11-30 |
Universite De Geneve |
Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
|
EP1888098A2
(en)
|
2005-05-25 |
2008-02-20 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin formulations
|
EP1891231A4
(en)
*
|
2005-05-25 |
2011-06-22 |
Novo Nordisk As |
GLYCOPEGYLATED FACTOR IX
|
MX2007015058A
(es)
*
|
2005-06-03 |
2008-01-28 |
Ambrx Inc |
Moleculas de interferon humano mejoradas y sus usos.
|
GB0511986D0
(en)
*
|
2005-06-13 |
2005-07-20 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
EP1893632B1
(en)
|
2005-06-17 |
2015-08-12 |
Novo Nordisk Health Care AG |
Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
|
EP2412744B1
(en)
|
2005-07-18 |
2014-01-22 |
Nektar Therapeutics |
Method for preparing branched functionalised polymers using branched polyol cores
|
KR100735784B1
(ko)
*
|
2005-07-20 |
2007-07-06 |
재단법인 목암생명공학연구소 |
인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
NZ565294A
(en)
|
2005-08-18 |
2010-06-25 |
Ambrx Inc |
Compositions of tRNA and uses thereof
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
US8679536B2
(en)
*
|
2005-08-24 |
2014-03-25 |
Actamax Surgical Materials, Llc |
Aldol-crosslinked polymeric hydrogel adhesives
|
US8679537B2
(en)
*
|
2005-08-24 |
2014-03-25 |
Actamaz Surgical Materials, LLC |
Methods for sealing an orifice in tissue using an aldol-crosslinked polymeric hydrogel adhesive
|
US7601798B2
(en)
*
|
2005-10-04 |
2009-10-13 |
Enzon Pharmaceuticals, Inc. |
Methods of preparing polymers having terminal amine groups using protected amine salts
|
AU2006344395B2
(en)
*
|
2005-10-13 |
2013-05-02 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive diseases
|
US9168286B2
(en)
*
|
2005-10-13 |
2015-10-27 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
EP1954710B1
(en)
*
|
2005-11-08 |
2011-03-02 |
Ambrx, Inc. |
Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
|
CA2626522A1
(en)
*
|
2005-11-16 |
2007-05-24 |
Ambrx, Inc. |
Methods and compositions comprising non-natural amino acids
|
CN101448512B
(zh)
*
|
2005-12-14 |
2015-11-25 |
Ambrx公司 |
含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
|
US7989554B2
(en)
|
2006-01-10 |
2011-08-02 |
Enzon Pharmaceuticals, Inc. |
Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
|
US10221228B2
(en)
|
2006-02-03 |
2019-03-05 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US9458444B2
(en)
|
2006-02-03 |
2016-10-04 |
Opko Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
US8048849B2
(en)
|
2006-02-03 |
2011-11-01 |
Modigene, Inc. |
Long-acting polypeptides and methods of producing same
|
US9249407B2
(en)
|
2006-02-03 |
2016-02-02 |
Opko Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
US10351615B2
(en)
|
2006-02-03 |
2019-07-16 |
Opko Biologics Ltd. |
Methods of treatment with long-acting growth hormone
|
US20140113860A1
(en)
|
2006-02-03 |
2014-04-24 |
Prolor Biotech Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US20150038413A1
(en)
|
2006-02-03 |
2015-02-05 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US8946155B2
(en)
|
2006-02-03 |
2015-02-03 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
JP5528710B2
(ja)
*
|
2006-02-28 |
2014-06-25 |
オリガシス コーポレイション |
アクリロイルオキシエチルホスホリルコリン含有ポリマー抱合体及びその製法
|
BRPI0708895A2
(pt)
|
2006-03-13 |
2011-06-28 |
Liat Mintz |
uso de variante de junção de grelina para tratar caquexia e/ou anorexia e/ou anorexia-caquexia e/ou subnutrição e/ou lipodistrofia e/ou atrofia muscular e/ou estimulação do apetite
|
WO2007123765A2
(en)
|
2006-03-31 |
2007-11-01 |
Human Genome Sciences Inc. |
Neutrokine-alpha and neutrokine-alpha splice variant
|
CN101622270B
(zh)
*
|
2006-04-12 |
2014-01-01 |
萨文特医药公司 |
用阳离子表面活性剂纯化蛋白质的方法
|
CN101062407A
(zh)
|
2006-04-29 |
2007-10-31 |
中国科学院上海生命科学研究院 |
促红细胞生成素在预防或治疗视网膜损伤中的用途
|
JP5313129B2
(ja)
|
2006-05-02 |
2013-10-09 |
アロザイン, インコーポレイテッド |
非天然アミノ酸置換ポリペプチド
|
US20080096819A1
(en)
*
|
2006-05-02 |
2008-04-24 |
Allozyne, Inc. |
Amino acid substituted molecules
|
EP2213733A3
(en)
|
2006-05-24 |
2010-12-29 |
Novo Nordisk Health Care AG |
Factor IX analogues having prolonged in vivo half life
|
US20090156629A1
(en)
*
|
2006-06-09 |
2009-06-18 |
Enzon Pharmaceuticals, Inc. |
Indenoisoquinoline-releasable polymer conjugates
|
DK2046369T3
(da)
*
|
2006-06-30 |
2015-11-30 |
Sigma Tau Pharma Ltd |
Rekombinant vært til fremstilling af l-asparaginase ii
|
US9187532B2
(en)
|
2006-07-21 |
2015-11-17 |
Novo Nordisk A/S |
Glycosylation of peptides via O-linked glycosylation sequences
|
US9505823B2
(en)
*
|
2006-08-07 |
2016-11-29 |
TEV A Biopharmaceuticals USA, Inc. |
Albumin-insulin fusion proteins
|
CN106190983B
(zh)
*
|
2006-09-08 |
2019-05-28 |
Ambrx公司 |
用于脊椎动物细胞的杂合抑制tRNA
|
DK2064333T3
(da)
*
|
2006-09-08 |
2014-05-05 |
Ambrx Inc |
Suppressor-trna-transkription i hvirveldyrceller
|
CN106008699A
(zh)
*
|
2006-09-08 |
2016-10-12 |
Ambrx公司 |
经修饰的人类血浆多肽或Fc骨架和其用途
|
KR20090057383A
(ko)
*
|
2006-09-15 |
2009-06-05 |
엔존 파마슈티컬즈, 인코포레이티드 |
다기능성 링커를 포함하는 표적화된 고분자 전구약물
|
US8110559B2
(en)
*
|
2006-09-15 |
2012-02-07 |
Enzon Pharmaceuticals, Inc. |
Hindered ester-based biodegradable linkers for oligonucleotide delivery
|
US8367065B2
(en)
*
|
2006-09-15 |
2013-02-05 |
Enzon Pharmaceuticals, Inc. |
Targeted polymeric prodrugs containing multifunctional linkers
|
US7985783B2
(en)
|
2006-09-21 |
2011-07-26 |
The Regents Of The University Of California |
Aldehyde tags, uses thereof in site-specific protein modification
|
NZ597098A
(en)
|
2006-09-28 |
2013-05-31 |
Merck Sharp & Dohme |
Use of pegylated il-10 to treat cancer
|
US20100075375A1
(en)
*
|
2006-10-03 |
2010-03-25 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates
|
PT2068907T
(pt)
|
2006-10-04 |
2018-01-15 |
Novo Nordisk As |
Açúcares e glicopéptidos peguilados ligados a glicerol
|
WO2008051383A2
(en)
*
|
2006-10-19 |
2008-05-02 |
Amgen Inc. |
Use of alcohol co-solvents to improve pegylation reaction yields
|
CN101168594B
(zh)
*
|
2006-10-24 |
2011-07-27 |
北京键凯科技有限公司 |
寡肽为骨架的聚乙二醇活性衍生物、其制备方法及与药物分子的结合物
|
PE20081140A1
(es)
*
|
2006-10-25 |
2008-09-22 |
Amgen Inc |
Agentes terapeuticos a base de peptidos derivados de toxinas
|
CN101541857B
(zh)
*
|
2006-11-27 |
2012-12-12 |
阿克塔马克斯手术器材有限责任公司 |
多官能聚环氧烷、水凝胶和组织粘合剂
|
TWI428346B
(zh)
*
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
EP2097140B1
(en)
*
|
2006-12-20 |
2012-09-26 |
Arkema Inc. |
Polymer encapsulation and/or binding
|
TW200835514A
(en)
*
|
2006-12-29 |
2008-09-01 |
Enzon Pharmaceuticals Inc |
Use of adenosine deaminase for treating pulmonary disease
|
CA2675411A1
(en)
*
|
2007-01-16 |
2008-07-24 |
Enzon Pharmaceuticals, Inc. |
Posaconazole polymer conjugates and methods of treatment using posaconazole and polymer conjugates thereof
|
AU2008210290B2
(en)
*
|
2007-02-01 |
2013-10-31 |
National Research Council Of Canada |
Formulations of lipophilic bioactive molecules
|
CN104163864B
(zh)
|
2007-03-30 |
2017-08-01 |
Ambrx公司 |
经修饰fgf‑21多肽和其用途
|
KR20150064246A
(ko)
|
2007-04-03 |
2015-06-10 |
바이오제너릭스 게엠베하 |
글리코페길화 g―csf를 이용하는 치료 방법
|
AU2008242748B2
(en)
|
2007-04-20 |
2013-12-05 |
Unikeris Limited |
Stable recombinant adenosine deaminase
|
EP2147122B1
(en)
*
|
2007-04-20 |
2014-07-16 |
Sigma-Tau Rare Diseases S.A. |
Enzymatic anticancer therapy
|
US8114630B2
(en)
|
2007-05-02 |
2012-02-14 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
CA2840407A1
(en)
*
|
2007-05-22 |
2008-12-18 |
Amgen Inc. |
Compositions and methods for producing bioactive fusion proteins
|
EP2170919B8
(en)
|
2007-06-12 |
2016-01-20 |
ratiopharm GmbH |
Improved process for the production of nucleotide sugars
|
TW200922624A
(en)
*
|
2007-07-11 |
2009-06-01 |
Enzon Pharmaceuticals Inc |
Polymeric drug delivery system containing a multi-substituted aromatic moiety
|
CL2008002399A1
(es)
*
|
2007-08-16 |
2009-01-02 |
Pharmaessentia Corp |
Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
|
CA2707840A1
(en)
|
2007-08-20 |
2009-02-26 |
Allozyne, Inc. |
Amino acid substituted molecules
|
US8207112B2
(en)
|
2007-08-29 |
2012-06-26 |
Biogenerix Ag |
Liquid formulation of G-CSF conjugate
|
US8088884B2
(en)
*
|
2007-09-27 |
2012-01-03 |
Serina Therapeutics, Inc. |
Multi-armed forms of activated polyoxazoline and methods of synthesis thereof
|
JP5868594B2
(ja)
|
2007-10-16 |
2016-02-24 |
バイオコン・リミテッドBiocon Limited |
経口投与可能な固形医薬組成物及びそのプロセス
|
EP2214731B1
(en)
*
|
2007-11-14 |
2014-05-14 |
Actamax Surgical Materials LLC |
Oxidized cationic polysaccharide-based polymer tissue adhesive for medical use
|
WO2009064977A2
(en)
|
2007-11-14 |
2009-05-22 |
E.I. Du Pont De Nemours And Company |
Dextran-based polymer tissue adhesive for medical use
|
NZ603812A
(en)
|
2007-11-20 |
2014-06-27 |
Ambrx Inc |
Modified insulin polypeptides and their uses
|
US8101706B2
(en)
|
2008-01-11 |
2012-01-24 |
Serina Therapeutics, Inc. |
Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
|
EP2669313B1
(en)
|
2008-01-11 |
2016-03-23 |
Serina Therapeutics, Inc. |
Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
|
JP5702150B2
(ja)
|
2008-02-08 |
2015-04-15 |
アンブルックス, インコーポレイテッドAmbrx, Inc. |
修飾されているレプチンポリペプチドおよびそれらの使用
|
WO2009108806A1
(en)
|
2008-02-27 |
2009-09-03 |
Novo Nordisk A/S |
Conjugated factor viii molecules
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
WO2009118300A1
(en)
|
2008-03-25 |
2009-10-01 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by down-regulating frizzled-4 and/or frizzled-1
|
JP2011519361A
(ja)
|
2008-04-14 |
2011-07-07 |
ハロザイム インコーポレイテッド |
修飾されたヒアルロニダーゼおよびヒアルロナン関連疾患および状態の治療における使用
|
WO2009128935A1
(en)
|
2008-04-16 |
2009-10-22 |
Biogen Idec Ma Inc. |
Method of isolating biomacromolecules using polyalkylene glycol and transition metals
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
US8932622B2
(en)
*
|
2008-06-03 |
2015-01-13 |
Actamax Surgical Materials, Llc |
Tissue coating for preventing undesired tissue-to-tissue adhesions
|
BRPI0915697A2
(pt)
|
2008-07-08 |
2016-02-10 |
Univ Texas |
inibidores de proliferação e ativação de transdutor de sinal e ativador de transcrição (stats)
|
US20100015231A1
(en)
*
|
2008-07-17 |
2010-01-21 |
E.I. Du Pont De Nemours And Company |
Low swell, long-lived hydrogel sealant
|
US8551136B2
(en)
|
2008-07-17 |
2013-10-08 |
Actamax Surgical Materials, Llc |
High swell, long-lived hydrogel sealant
|
EP3225248B1
(en)
|
2008-07-23 |
2023-06-07 |
Ambrx, Inc. |
Modified bovine g-csf polypeptides and their uses
|
CN102131844B
(zh)
|
2008-07-31 |
2016-03-02 |
药华医药股份有限公司 |
肽-聚合物缀合物
|
AU2009284840B2
(en)
*
|
2008-08-25 |
2012-09-27 |
Biopolymed Inc. |
Biopolymer conjugates comprising an interleukin-11 analog
|
KR101647164B1
(ko)
|
2008-09-26 |
2016-08-09 |
암브룩스, 인코포레이티드 |
변형된 동물 에리트로포이에틴 폴리펩티드 및 이의 용도
|
PT2337846T
(pt)
|
2008-09-26 |
2018-04-05 |
Ambrx Inc |
Vacinas e microrganismos dependentes da replicação de aminoácidos não naturais
|
WO2010052288A1
(en)
|
2008-11-07 |
2010-05-14 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Teneurin and cancer
|
US8466327B2
(en)
|
2008-11-19 |
2013-06-18 |
Actamax Surgical Materials, Llc |
Aldehyde-functionalized polyethers and method of making same
|
US9044529B2
(en)
*
|
2008-11-19 |
2015-06-02 |
Actamax Surgical Materials, Llc |
Hydrogel tissue adhesive formed from aminated polysaccharide and aldehyde-functionalized multi-arm polyether
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之egfr/igfir結合分子
|
JP5670913B2
(ja)
|
2008-12-09 |
2015-02-18 |
ハロザイム インコーポレイテッド |
延長された可溶性ph20ポリペプチドおよびその使用
|
KR20110102420A
(ko)
|
2008-12-10 |
2011-09-16 |
메르사나 테라퓨틱스, 인코포레이티드 |
생분해성 및 생체적합성 캄토테신-중합체 접합체의 약학 제제
|
CN102256625B
(zh)
|
2008-12-17 |
2013-11-20 |
默沙东公司 |
单和双peg il10的生产和用途
|
US20100160960A1
(en)
*
|
2008-12-19 |
2010-06-24 |
E. I. Du Pont De Nemours And Company |
Hydrogel tissue adhesive having increased degradation time
|
US20110046060A1
(en)
|
2009-08-24 |
2011-02-24 |
Amunix Operating, Inc., |
Coagulation factor IX compositions and methods of making and using same
|
WO2010093993A2
(en)
*
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
WO2010100247A1
(en)
|
2009-03-06 |
2010-09-10 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Novel therapy for anxiety
|
ES2593862T3
(es)
*
|
2009-03-09 |
2016-12-13 |
Molecular Express, Inc. |
Métodos y composiciones de formulación liposomal de antígenos y usos de los mismos
|
US8580732B2
(en)
*
|
2009-04-07 |
2013-11-12 |
Duke University |
Peptide therapy for hyperglycemia
|
WO2010118284A1
(en)
|
2009-04-09 |
2010-10-14 |
E. I. Du Pont De Nemours And Company |
Hydrogel tissue adhesive having reduced degradation time
|
EP2241323A1
(en)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W and brain cancers
|
US20100330033A1
(en)
*
|
2009-04-16 |
2010-12-30 |
Nian Wu |
Protein-carrier conjugates
|
ES2966234T3
(es)
|
2009-06-09 |
2024-04-18 |
Prolong Pharmaceuticals Llc |
Composiciones de hemoglobina
|
EP2261662B1
(en)
*
|
2009-06-10 |
2014-01-22 |
Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften |
Novel synthetic blocking reagents
|
KR101861547B1
(ko)
|
2009-06-25 |
2018-07-02 |
크레알타 파마슈티칼스 엘엘씨 |
페길화된 유리카아제 치료 중에 혈청 요산을 모니터링하여 주입 반응의 위험성 및 반응의 항체매개 상실을 예측하는 방법 및 키트
|
WO2011002888A2
(en)
|
2009-07-02 |
2011-01-06 |
E. I. Du Pont De Nemours And Company |
Hydrogel tissue adhesive for medical use
|
US8580950B2
(en)
|
2009-07-02 |
2013-11-12 |
Actamax Surgical Materials, Llc |
Aldehyde-functionalized polysaccharides
|
WO2011002956A1
(en)
|
2009-07-02 |
2011-01-06 |
E. I. Du Pont De Nemours And Company |
Aldehyde-functionalized polysaccharides
|
US8796242B2
(en)
|
2009-07-02 |
2014-08-05 |
Actamax Surgical Materials, Llc |
Hydrogel tissue adhesive for medical use
|
US9663778B2
(en)
|
2009-07-09 |
2017-05-30 |
OPKO Biologies Ltd. |
Long-acting coagulation factors and methods of producing same
|
EP2292266A1
(en)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Treating cancer by modulating copine III
|
CA2773596C
(en)
|
2009-09-15 |
2017-11-28 |
Kaneka Corporation |
Modified erythropoietin to which water-soluble long-chain molecule is added
|
AU2010296017C1
(en)
|
2009-09-17 |
2013-09-19 |
Takeda Pharmaceutical Company Limited |
Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
|
EP2480573A1
(en)
|
2009-09-22 |
2012-08-01 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
WO2011060233A1
(en)
|
2009-11-11 |
2011-05-19 |
The Trustees Of The University Of Pennsylvania |
Anti-tem1 antibodies and uses thereof
|
WO2011075185A1
(en)
|
2009-12-18 |
2011-06-23 |
Oligasis |
Targeted drug phosphorylcholine polymer conjugates
|
AU2010341518B2
(en)
|
2009-12-21 |
2014-01-09 |
Ambrx, Inc. |
Modified porcine somatotropin polypeptides and their uses
|
CN102753573A
(zh)
|
2009-12-21 |
2012-10-24 |
Ambrx公司 |
经过修饰的牛促生长素多肽和其用途
|
WO2011107586A1
(en)
|
2010-03-05 |
2011-09-09 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, |
Smoc1, tenascin-c and brain cancers
|
EP3815708A1
(en)
|
2010-03-05 |
2021-05-05 |
Omeros Corporation |
Chimeric inhibitor molecules of complement activation
|
EP2561076A1
(en)
|
2010-04-19 |
2013-02-27 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Modulating xrn1
|
US9018348B2
(en)
|
2010-04-27 |
2015-04-28 |
Agency For Science, Technology And Research |
eIF4E binding peptides
|
GB201007356D0
(en)
|
2010-04-30 |
2010-06-16 |
Leverton Licence Holdings Ltd |
Conjugated factor VIIa
|
US8828181B2
(en)
|
2010-04-30 |
2014-09-09 |
E I Du Pont De Nemours And Company |
Temperature switchable adhesives comprising a crystallizable oil
|
EP2569331A1
(en)
|
2010-05-10 |
2013-03-20 |
Perseid Therapeutics LLC |
Polypeptide inhibitors of vla4
|
US20130089538A1
(en)
|
2010-06-10 |
2013-04-11 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
JP5825507B2
(ja)
*
|
2010-06-25 |
2015-12-02 |
日油株式会社 |
分岐型ヘテロポリエチレングリコール
|
US10040761B2
(en)
|
2010-06-25 |
2018-08-07 |
Nof Corporation |
Branched hetero polyethylene glycol and intermediate
|
ES2661089T3
(es)
|
2010-07-20 |
2018-03-27 |
Halozyme Inc. |
Métodos de tratamiento o prevención de los efectos secundarios adversos asociados con la administración de un agente anti-hialuronano
|
US8409703B2
(en)
|
2010-07-23 |
2013-04-02 |
E I Du Pont De Nemours And Company |
Temperature switchable adhesive assemblies with temperature non-switchable tack
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
PL2605789T3
(pl)
|
2010-08-17 |
2019-11-29 |
Ambrx Inc |
Zmodyfikowane polipeptydy relaksyny i ich zastosowania
|
WO2012032143A1
(en)
|
2010-09-10 |
2012-03-15 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Phosphorylated twist1 and metastasis
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
US20140093506A1
(en)
|
2010-11-15 |
2014-04-03 |
Marc Buehler |
Anti-fungal-agents
|
US9783601B2
(en)
|
2010-12-01 |
2017-10-10 |
Alderbio Holdings Llc |
Methods of preventing inflammation and treating pain using anti-NGF compositions
|
EP2907504B1
(en)
|
2011-02-08 |
2017-06-28 |
Halozyme, Inc. |
Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
|
US20130337537A1
(en)
|
2011-03-02 |
2013-12-19 |
Novo Nordisk A/S |
Coagulation factor-targeting to tlt-1 on activated platelets
|
KR20140145947A
(ko)
|
2011-03-16 |
2014-12-24 |
암젠 인크 |
Nav1.3과 nav1.7의 유효한 선별적 저해제
|
US9708393B2
(en)
|
2011-05-20 |
2017-07-18 |
Alderbio Holdings Llc |
Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
|
CN107602700B
(zh)
|
2011-05-20 |
2021-12-17 |
H.伦德贝克公司 |
抗cgrp组合物及其用途
|
MX365813B
(es)
|
2011-05-20 |
2019-06-14 |
Alderbio Holdings Llc |
Uso de anticuerpos anti-cgrp o anti-cgrp o fragmentos de anticuerpo para tratar o prevenir formas crónicas y agudas de diarrea.
|
US10166295B2
(en)
|
2011-06-02 |
2019-01-01 |
Opko Biologics Ltd. |
Pegylated OXM variants
|
EP2717911A1
(en)
|
2011-06-06 |
2014-04-16 |
Novartis Forschungsstiftung, Zweigniederlassung |
Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
|
SI2717898T1
(sl)
|
2011-06-10 |
2019-07-31 |
Bioverativ Therapeutics Inc. |
Spojine prokoagulantov in metode za njihovo uporabo
|
CA2839512C
(en)
|
2011-06-17 |
2018-01-02 |
Halozyme, Inc. |
Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme
|
US9993529B2
(en)
|
2011-06-17 |
2018-06-12 |
Halozyme, Inc. |
Stable formulations of a hyaluronan-degrading enzyme
|
US20130090294A1
(en)
|
2011-06-28 |
2013-04-11 |
Alternative Innovative Technologies Llc |
Novel methods of use of hsp70 for increased performance or treatment of hsp70 related disorders
|
WO2013004607A1
(en)
|
2011-07-01 |
2013-01-10 |
Bayer Intellectual Property Gmbh |
Relaxin fusion polypeptides and uses thereof
|
JP6208658B2
(ja)
|
2011-07-05 |
2017-10-04 |
バイオアシス テクノロジーズ インコーポレイテッド |
p97−抗体結合体および使用方法
|
WO2013040501A1
(en)
|
2011-09-16 |
2013-03-21 |
Pharmathene, Inc. |
Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
|
US9937241B2
(en)
|
2011-10-14 |
2018-04-10 |
Alternative Innovative Technologies Llc |
Degradation resistant HSP70 formulations and uses thereof
|
SG11201401797TA
(en)
|
2011-10-24 |
2014-09-26 |
Halozyme Inc |
Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
|
US20140294732A1
(en)
|
2011-11-08 |
2014-10-02 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Early diagnostic of neurodegenerative diseases
|
WO2013068431A1
(en)
|
2011-11-08 |
2013-05-16 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
WO2013101509A2
(en)
|
2011-12-15 |
2013-07-04 |
Alternative Innovative Technologies Llc |
Hsp70 fusion protein conjugates and uses thereof
|
ES2749620T3
(es)
|
2011-12-30 |
2020-03-23 |
Halozyme Inc |
Variantes de polipéptidos de PH20, formulaciones y usos de los mismos
|
EP2800583A1
(en)
|
2012-01-02 |
2014-11-12 |
Novartis AG |
Cdcp1 and breast cancer
|
CN111499760A
(zh)
|
2012-01-12 |
2020-08-07 |
比奥贝拉蒂治疗公司 |
嵌合因子viii多肽及其用途
|
PT2814840T
(pt)
|
2012-02-15 |
2020-01-28 |
Bioverativ Therapeutics Inc |
Composições de fator viii e métodos de produção e utilização das mesmas
|
EP2822577B1
(en)
|
2012-02-15 |
2019-02-06 |
Bioverativ Therapeutics Inc. |
Recombinant factor viii proteins
|
CN104136626B
(zh)
|
2012-03-01 |
2017-05-03 |
诺沃—诺迪斯克有限公司 |
N‑末端修饰的寡肽及其用途
|
US20150266961A1
(en)
|
2012-03-29 |
2015-09-24 |
Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute |
Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
|
MX360092B
(es)
|
2012-04-04 |
2018-10-19 |
Halozyme Inc |
Terapia de combinación con un agente antihialuronano y un taxano orientado a tumor.
|
EP2838552A4
(en)
|
2012-04-19 |
2016-05-18 |
Opko Biolog Ltd |
OXYNTOMODULIN VARIANTS WITH EXTENDED ACTION AND PROCESSES FOR PRODUCING SAME
|
WO2013162748A1
(en)
|
2012-04-27 |
2013-10-31 |
The Trustees Of The University Of Pennsylvania |
Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof
|
MX363119B
(es)
|
2012-05-01 |
2019-03-11 |
Novo Nordisk As |
Composicion farmaceutica.
|
CA2875599C
(en)
|
2012-06-04 |
2020-08-18 |
Opko Biologics Ltd. |
Pegylated oxyntomodulin variants
|
EP3505534A1
(en)
|
2012-06-08 |
2019-07-03 |
Sutro Biopharma, Inc. |
Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
|
WO2013185113A1
(en)
|
2012-06-08 |
2013-12-12 |
Biogen Idec Ma Inc. |
Procoagulant compounds
|
CN104427995A
(zh)
|
2012-06-08 |
2015-03-18 |
比奥根艾迪克Ma公司 |
嵌合凝血因子
|
GB201210770D0
(en)
*
|
2012-06-18 |
2012-08-01 |
Polytherics Ltd |
Novel conjugation reagents
|
DK2863955T3
(da)
|
2012-06-26 |
2017-01-23 |
Sutro Biopharma Inc |
Modificerede fc-proteiner, der omfatter stedsspecifikke ikke-naturlige aminosyrerester, konjugater heraf, fremgangsmåder til fremstilling heraf og fremgangsmåder til anvendelse heraf
|
US20150218238A1
(en)
|
2012-06-29 |
2015-08-06 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
Treating diseases by modulating a specific isoform of mkl1
|
WO2014006114A1
(en)
|
2012-07-05 |
2014-01-09 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
RS59876B1
(sr)
|
2012-07-11 |
2020-03-31 |
Bioverativ Therapeutics Inc |
Kompleks faktora viii sa xten i proteinom fon vilebrandovog faktora, i njihova primena
|
IN2015DN00552A
(da)
|
2012-07-19 |
2015-06-26 |
Redwood Bioscience Inc |
|
US9932565B2
(en)
|
2012-07-31 |
2018-04-03 |
Bioasis Technologies, Inc. |
Dephosphorylated lysosomal storage disease proteins and methods of use thereof
|
AU2013302540B2
(en)
|
2012-08-16 |
2018-02-15 |
Ipierian, Inc. |
Methods of treating a tauopathy
|
SI2890402T1
(sl)
|
2012-08-31 |
2019-07-31 |
Sutro Biopharma, Inc. |
Modificirane aminokisline vsebujoče acido skupino
|
US9278124B2
(en)
|
2012-10-16 |
2016-03-08 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
CN110818798A
(zh)
|
2012-10-25 |
2020-02-21 |
美国比奥维拉迪维股份有限公司 |
抗补体C1s抗体和其用途
|
WO2014071206A1
(en)
|
2012-11-02 |
2014-05-08 |
True North Therapeutics, Inc. |
Anti-complement c1s antibodies and uses thereof
|
KR20150083121A
(ko)
|
2012-11-12 |
2015-07-16 |
레드우드 바이오사이언스 인코포레이티드 |
화합물, 및 컨쥬게이트의 제조방법
|
US9310374B2
(en)
|
2012-11-16 |
2016-04-12 |
Redwood Bioscience, Inc. |
Hydrazinyl-indole compounds and methods for producing a conjugate
|
KR20150085064A
(ko)
|
2012-11-16 |
2015-07-22 |
더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 |
단백질 화학적 변형을 위한 피크테 스펭글러 결합
|
US8859705B2
(en)
|
2012-11-19 |
2014-10-14 |
Actamax Surgical Materials Llc |
Hydrogel tissue adhesive having decreased gelation time and decreased degradation time
|
SG10201610223PA
(en)
|
2012-11-20 |
2017-02-27 |
Opko Biolog Ltd |
Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
|
WO2014080350A1
(en)
|
2012-11-21 |
2014-05-30 |
The Governors Of The University Of Alberta |
Immunomodulatory peptides and methods of use thereof
|
ES2875957T3
(es)
|
2012-12-20 |
2021-11-11 |
Amgen Inc |
Agonistas del receptor APJ y usos de los mismos
|
US9675678B2
(en)
|
2013-01-29 |
2017-06-13 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods for treatment of homocystinuria
|
US9272075B2
(en)
|
2013-02-04 |
2016-03-01 |
W.L. Gore & Associates, Inc. |
Coating for substrate
|
BR112015017062B1
(pt)
|
2013-02-04 |
2020-04-14 |
Gore & Ass |
revestimento para substrato
|
UY35397A
(es)
|
2013-03-12 |
2014-10-31 |
Amgen Inc |
INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
|
CA2906003C
(en)
|
2013-03-13 |
2021-07-06 |
Bioasis Technologies Inc. |
Fragments of p97 and uses thereof
|
EP3470416B1
(en)
|
2013-03-14 |
2022-04-27 |
Alere San Diego, Inc. |
6-acetylmorphine analogs, and methods for their synthesis and use
|
CN105209497B
(zh)
|
2013-03-15 |
2021-09-07 |
诺和诺德股份有限公司 |
能够特异性结合组织因子途径抑制物上的两个表位的抗体
|
JP6460366B2
(ja)
|
2013-03-27 |
2019-01-30 |
日油株式会社 |
アミノ基を一つ有するポリエチレングリコールの精製方法
|
JP2016519108A
(ja)
|
2013-04-18 |
2016-06-30 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
インターロイキン−10を疾病及び疾患の治療に用いる方法
|
ES2877093T3
(es)
|
2013-04-23 |
2021-11-16 |
Nizyme Inc |
Procedimientos y composiciones para el tratamiento de enfermedades
|
CA3173775A1
(en)
|
2013-06-10 |
2014-12-18 |
Ipierian, Inc. |
Methods of treating a tauopathy
|
EP3010527B1
(en)
|
2013-06-17 |
2018-08-08 |
Armo Biosciences, Inc. |
Method for assessing protein identity and stability
|
NZ713904A
(en)
|
2013-06-28 |
2022-02-25 |
Bioverativ Therapeutics Inc |
Thrombin cleavable linker with xten and its uses thereof
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ph20玻尿酸酶變異體及其用途
|
TWI712419B
(zh)
|
2013-07-03 |
2020-12-11 |
美商艾爾德生物製藥股份有限公司 |
使用抗cgrp抗體之葡萄糖代謝的調節
|
EP3019522B1
(en)
|
2013-07-10 |
2017-12-13 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
EP3027659B1
(en)
|
2013-07-29 |
2020-12-09 |
Actamax Surgical Materials LLC |
Low swell tissue adhesive and sealant formulations
|
US20160178610A1
(en)
|
2013-08-07 |
2016-06-23 |
Friedrich Miescher Institute For Biomedical Research |
New screening method for the treatment Friedreich's ataxia
|
TW202003554A
(zh)
|
2013-08-14 |
2020-01-16 |
美商百歐維拉提夫治療公司 |
因子viii-xten融合物及其用途
|
AU2014312190A1
(en)
|
2013-08-28 |
2016-02-18 |
Bioasis Technologies Inc. |
CNS-targeted conjugates of antibodies
|
AU2014311432A1
(en)
|
2013-08-30 |
2016-03-03 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
US10702608B2
(en)
|
2013-09-08 |
2020-07-07 |
Kodiak Sciences Inc. |
Factor VIII zwitterionic polymer conjugates
|
ES2900425T3
(es)
|
2013-09-25 |
2022-03-16 |
Bioverativ Therapeutics Inc |
Métodos de inactivación vírica en columna
|
EP3055298B1
(en)
|
2013-10-11 |
2020-04-29 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
US20150158926A1
(en)
|
2013-10-21 |
2015-06-11 |
Opko Biologics, Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US10584147B2
(en)
|
2013-11-08 |
2020-03-10 |
Biovertiv Therapeutics Inc. |
Procoagulant fusion compound
|
KR20160079114A
(ko)
|
2013-11-11 |
2016-07-05 |
아르모 바이오사이언시스 인코포레이티드 |
질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
|
US9493413B2
(en)
|
2013-11-27 |
2016-11-15 |
Redwood Bioscience, Inc. |
Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
|
CN105899230B
(zh)
|
2013-11-27 |
2020-06-09 |
伊皮埃里安股份有限公司 |
治疗tau病变的方法
|
SI4176894T1
(sl)
|
2014-01-10 |
2024-07-31 |
Bioverativ Therapeutics Inc. |
Himerni proteini faktorja VIII in njihova uporaba
|
WO2015187295A2
(en)
|
2014-06-02 |
2015-12-10 |
Armo Biosciences, Inc. |
Methods of lowering serum cholesterol
|
AU2015274574B2
(en)
|
2014-06-10 |
2019-10-10 |
Amgen Inc. |
Apelin polypeptides
|
EP3154579A1
(en)
|
2014-06-13 |
2017-04-19 |
Friedrich Miescher Institute for Biomedical Research |
New treatment against influenza virus
|
EP3157535A1
(en)
|
2014-06-23 |
2017-04-26 |
Friedrich Miescher Institute for Biomedical Research |
Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
|
WO2016033555A1
(en)
|
2014-08-28 |
2016-03-03 |
Halozyme, Inc. |
Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
|
US20170298360A1
(en)
|
2014-09-24 |
2017-10-19 |
Friedrich Miescher Institute For Biomedical Research |
Lats and breast cancer
|
TN2017000109A1
(en)
|
2014-09-26 |
2018-07-04 |
Bayer Pharma AG |
Stabilized adrenomedullin derivatives and use thereof
|
ES2753391T3
(es)
|
2014-10-14 |
2020-04-08 |
Halozyme Inc |
Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas
|
KR20170068553A
(ko)
|
2014-10-14 |
2017-06-19 |
아르모 바이오사이언시스 인코포레이티드 |
인터류킨-15 조성물 및 이의 용도
|
ES2941234T3
(es)
|
2014-10-22 |
2023-05-19 |
Armo Biosciences Inc |
Métodos de uso de la interleucina-10 para el tratamiento de enfermedades y trastornos
|
JP6949711B2
(ja)
|
2014-10-23 |
2021-10-20 |
エヌジーエム バイオファーマシューティカルス,インコーポレーテッド |
ペプチドバリアントを含む医薬組成物及びその使用方法
|
MA40835A
(fr)
|
2014-10-23 |
2017-08-29 |
Biogen Ma Inc |
Anticorps anti-gpiib/iiia et leurs utilisations
|
UY36370A
(es)
|
2014-10-24 |
2016-04-29 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Polipéptidos fgf-21 modificados y sus usos
|
MA40861A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Anticorps anti-glycoprotéines iib/iiia
|
HUE064909T2
(hu)
|
2014-11-06 |
2024-04-28 |
Pharmaessentia Corp |
Adagolási rendszer pegilált interferonhoz
|
CN107108687B
(zh)
|
2014-11-19 |
2019-10-29 |
Nzp英国有限公司 |
作为制备类固醇FXR调节剂的中间体的5β-6-烷基-7-羟基-3-酮类固醇
|
EA033427B1
(ru)
|
2014-11-19 |
2019-10-31 |
Nzp Uk Ltd |
6-алкил-7-гидрокси-4-ен-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
|
BR112017010498A2
(pt)
|
2014-11-19 |
2017-12-26 |
Axon Neuroscience Se |
anticorpos tau humanizados em doença de alzheimer
|
KR102527821B1
(ko)
|
2014-11-19 |
2023-05-02 |
엔제트피 유케이 리미티드 |
스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드
|
PL3221333T3
(pl)
|
2014-11-19 |
2020-01-31 |
NZP UK Limited |
Steroidy, 6.alfa-alkilo-3,7-diony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
|
WO2016100838A2
(en)
|
2014-12-19 |
2016-06-23 |
Alder Biopharmaceuticals, Inc. |
Humanized anti-acth antibodies and use thereof
|
WO2016126615A1
(en)
|
2015-02-03 |
2016-08-11 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
KR20170141692A
(ko)
|
2015-05-01 |
2017-12-26 |
알리스타 파마슈티컬즈, 인크. |
안구 장애를 치료하기 위한 아디포넥틴 펩티드모방체
|
AU2016268403A1
(en)
|
2015-05-28 |
2017-12-07 |
Armo Biosciences, Inc. |
Pegylated interleukin-10 for use in treating cancer
|
CA2986774A1
(en)
|
2015-05-29 |
2016-12-08 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
EP3302571B1
(en)
|
2015-05-29 |
2020-11-18 |
OPKO Biologics Ltd. |
Pegylated oxyntomodulin variants
|
CA2989138C
(en)
|
2015-06-15 |
2022-11-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for treating cognitive impairment or decline comprising tissue inhibitor of mettaloproteinase-2 (timp-2)
|
ES2893616T3
(es)
|
2015-06-19 |
2022-02-09 |
Opko Biologics Ltd |
Factores de coagulación de acción prolongada y métodos para la producción de los mismos
|
JP6909203B2
(ja)
|
2015-08-03 |
2021-07-28 |
バイオベラティブ セラピューティクス インコーポレイテッド |
第ix因子融合タンパク質及びそれらの製造方法及び使用方法
|
CA2994971A1
(en)
|
2015-08-12 |
2017-02-16 |
Cell Machines, Inc. |
Methods and compositions related to long half-life coagulation complexes
|
AU2016312510A1
(en)
|
2015-08-25 |
2018-03-08 |
Armo Biosciences, Inc. |
Methods of using Interleukin-10 for treating diseases and disorders
|
IL257798B1
(en)
|
2015-09-02 |
2024-06-01 |
Immutep Sas |
Antibodies against LAG-3
|
WO2017059338A1
(en)
*
|
2015-10-02 |
2017-04-06 |
Cornell University |
Enzyme-responsive peptide nanofiber compositions and uses thereof
|
US20180348224A1
(en)
|
2015-10-28 |
2018-12-06 |
Friedrich Miescher Institute For Biomedical Resear Ch |
Tenascin-w and biliary tract cancers
|
NZ741552A
(en)
|
2015-11-09 |
2022-04-29 |
Univ Colorado Regents |
Compositions and methods for treatment of homocystinuria
|
EP3888672A1
(en)
|
2015-11-09 |
2021-10-06 |
NGM Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders
|
RU2018130757A
(ru)
|
2016-01-27 |
2020-02-27 |
Сутро Биофарма, Инк. |
Конъюгаты антитела к cd74, композиции, содержащие конъюгаты антитела к cd74, и способы использования конъюгатов антитела к cd74
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
KR20240096672A
(ko)
|
2016-04-04 |
2024-06-26 |
바이오버라티브 유에스에이 인코포레이티드 |
항-보체 인자 bb 항체 및 이의 용도
|
SG11201808632YA
(en)
|
2016-04-15 |
2018-10-30 |
Alder Biopharmaceuticals Inc |
Anti-pacap antibodies and uses thereof
|
GB201608777D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Compounds
|
CA3024622A1
(en)
|
2016-05-18 |
2017-11-23 |
Alere San Diego, Inc. |
2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine analogs and methods for their synthesis and use
|
GB201608776D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Methods and compounds
|
WO2017212494A1
(en)
|
2016-06-09 |
2017-12-14 |
Opko Biologics Ltd. |
Long-acting oxyntomodulin formulation and methods of producing and administering same
|
PT3481855T
(pt)
|
2016-07-11 |
2023-11-27 |
Opko Biologics Ltd |
Fator vii de coagulação de ação prolongada e métodos de produção do mesmo
|
MA46568A
(fr)
|
2016-10-24 |
2019-08-28 |
Novo Nordisk As |
Dosage biologique de formulations d'insuline
|
KR102459469B1
(ko)
|
2016-11-14 |
2022-10-26 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
US20200031895A1
(en)
|
2016-12-16 |
2020-01-30 |
Biogen Ma Inc. |
Stabilized proteolytically activated growth differentiation factor 11
|
BR112019016139A2
(pt)
|
2017-02-08 |
2020-04-07 |
Bristol-Myers Squibb Company |
polipeptídio de relaxina modificada compreendendo um melhorador farmacocinético e usos do mesmo
|
JP6935059B2
(ja)
|
2017-03-30 |
2021-09-15 |
日油株式会社 |
カルボキシル基を一つ有するポリエチレングリコールの精製方法
|
US11324811B2
(en)
|
2017-04-17 |
2022-05-10 |
The Regents Of The University Of Colorado, A Body Corporate |
Optimization of enzyme replacement therapy for treatment of homocystinuria
|
CA3066915A1
(en)
|
2017-06-11 |
2018-12-20 |
Molecular Express, Inc. |
Methods and compositions for substance use disorder vaccine formulations and uses thereof
|
SG11201912071QA
(en)
|
2017-06-22 |
2020-01-30 |
Catalyst Biosciences Inc |
Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
|
US20200207859A1
(en)
|
2017-07-26 |
2020-07-02 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
WO2019030692A1
(en)
|
2017-08-10 |
2019-02-14 |
Friedrich Miescher Institute For Biomedical Research |
HDAC6 AND AGGREGATION OF PROTEINS
|
EP3684814A1
(en)
|
2017-09-18 |
2020-07-29 |
Sutro Biopharma, Inc. |
Anti-folate receptor alpha antibody conjugates and their uses
|
CN111315398A
(zh)
|
2017-11-10 |
2020-06-19 |
阿尔莫生物科技股份有限公司 |
白介素-10与免疫检查点途径抑制剂的组合的组合物和使用方法
|
WO2019133399A1
(en)
|
2017-12-26 |
2019-07-04 |
Becton, Dickinson And Company |
Deep ultraviolet-excitable water-solvated polymeric dyes
|
CA3094112A1
(en)
|
2018-03-28 |
2019-10-03 |
Bristol-Myers Squibb Company |
Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
|
EP3775052B1
(en)
|
2018-03-30 |
2024-06-05 |
Becton, Dickinson and Company |
Water-soluble polymeric dyes having pendant chromophores
|
WO2019211842A1
(en)
|
2018-04-30 |
2019-11-07 |
Opko Biologics Ltd. |
Long-acting human growth hormone-antagonists and methods of producing the same
|
WO2019222435A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
EP3793588A1
(en)
|
2018-05-18 |
2021-03-24 |
Bioverativ Therapeutics Inc. |
Methods of treating hemophilia a
|
JP7097465B2
(ja)
|
2018-06-19 |
2022-07-07 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
キメラ抗原受容体細胞療法と併用するil-10剤の組成およびその使用方法
|
EP3817720A2
(en)
|
2018-07-03 |
2021-05-12 |
Bristol-Myers Squibb Company |
Fgf21 formulations
|
US20220162336A1
(en)
|
2018-07-22 |
2022-05-26 |
Bioasis Technologies, Inc. |
Treatment of lymphatic metastases
|
PT3849614T
(pt)
|
2018-09-11 |
2024-02-28 |
Ambrx Inc |
Conjugados de polipeptídeos de interleucina-2 e suas utilizações
|
WO2020060944A1
(en)
|
2018-09-17 |
2020-03-26 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
EP3867265A1
(en)
|
2018-10-19 |
2021-08-25 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
EP3902913A1
(en)
|
2018-12-28 |
2021-11-03 |
Catalyst Biosciences, Inc. |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
KR20210126088A
(ko)
|
2019-02-11 |
2021-10-19 |
옵코 바이오로직스 리미티드 |
지속성 glp-2 유사체
|
CA3128081A1
(en)
|
2019-02-12 |
2020-08-20 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-tlr agonist conjugates
|
EP3962951A1
(en)
|
2019-05-03 |
2022-03-09 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
CN114269749A
(zh)
|
2019-06-10 |
2022-04-01 |
苏特罗生物制药公司 |
5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物
|
WO2020257235A1
(en)
|
2019-06-17 |
2020-12-24 |
Sutro Biopharma, Inc. |
1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
|
US20220387608A1
(en)
|
2019-06-18 |
2022-12-08 |
Bayer Aktiengesellschaft |
Adrenomedullin-analogues for long-term stabilization and their use
|
JP2022545917A
(ja)
|
2019-08-27 |
2022-11-01 |
トニックス ファーマ リミテッド |
修飾tff2ポリペプチド
|
WO2021072265A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
US20230346957A1
(en)
|
2020-01-08 |
2023-11-02 |
Bristol-Myers Squibb Company |
Fgf-21 conjugate formulations
|
US20230095053A1
(en)
|
2020-03-03 |
2023-03-30 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
MX2022011163A
(es)
|
2020-03-11 |
2022-10-18 |
Ambrx Inc |
Conjugados de polipeptidos de interleucina-2 y sus usos.
|
SG10202003296VA
(en)
|
2020-04-06 |
2021-11-29 |
H Lundbeck As |
Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies
|
BR112022022045A2
(pt)
|
2020-04-30 |
2023-01-10 |
Sairopa B V |
Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao cd103 humano, um ou mais ácidos nucleicos, sistema de expressão, célula hospedeira, composição, métodos de produção de um anticorpo ou fragmento de ligação ao antígeno, para detectar a presença de cd103 em uma amostra biológica, para tratar ou prevenir uma condição mediada por sinalização de cd103 em um indivíduo em necessidade, para inibir a sinalização de cd103 em uma célula, para inibir a ligação de cd103 à e-caderina presente em uma célula, para retirar as células que expressam cd103 em um indivíduo, para tratar ou prevenir uma doença e agente de imageamento
|
US20210355468A1
(en)
|
2020-05-18 |
2021-11-18 |
Bioasis Technologies, Inc. |
Compositions and methods for treating lewy body dementia
|
US20210393787A1
(en)
|
2020-06-17 |
2021-12-23 |
Bioasis Technologies, Inc. |
Compositions and methods for treating frontotemporal dementia
|
JP2023538533A
(ja)
|
2020-08-07 |
2023-09-08 |
ブリストル-マイヤーズ スクイブ カンパニー |
線維症の処置のための、ccr2/5拮抗剤と組み合わせたfgf21
|
EP3954393A1
(en)
|
2020-08-13 |
2022-02-16 |
Bioasis Technologies Inc. |
Combination therapies for delivery across the blood brain barrier
|
US20230302150A1
(en)
|
2020-08-20 |
2023-09-28 |
Ambrx, Inc. |
Antibody-tlr agonist conjugates, methods and uses thereof
|
WO2022103983A2
(en)
|
2020-11-11 |
2022-05-19 |
Sutro Biopharma, Inc. |
Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
|
WO2022115597A1
(en)
|
2020-11-25 |
2022-06-02 |
Bristol-Myers Squibb Company |
Methods of treating liver diseases
|
KR20240004342A
(ko)
|
2021-04-03 |
2024-01-11 |
암브룩스, 인코포레이티드 |
항-her2 항체-약물 접합체 및 이의 용도
|
CN117396231A
(zh)
|
2021-04-30 |
2024-01-12 |
新基公司 |
使用抗BCMA抗体药物缀合物(ADC)与γ分泌酶抑制剂(GSI)的组合的组合疗法
|
AU2022330343A1
(en)
|
2021-08-20 |
2024-02-08 |
Bayer Aktiengesellschaft |
Process for the preparation of pegylated adrenomedullin, its intermediates and use thereof
|
AU2022333323A1
(en)
|
2021-08-27 |
2024-02-29 |
H. Lundbeck A/S |
Treatment of cluster headache using anti-cgrp antibodies
|
EP4155349A1
(en)
|
2021-09-24 |
2023-03-29 |
Becton, Dickinson and Company |
Water-soluble yellow green absorbing dyes
|
WO2024006272A1
(en)
|
2022-06-27 |
2024-01-04 |
Sutro Biopharma, Inc. |
β-GLUCURONIDE LINKER-PAYLOADS, PROTEIN CONJUGATES THEREOF, AND METHODS THEREOF
|
WO2024006542A1
(en)
|
2022-06-30 |
2024-01-04 |
Sutro Biopharma, Inc. |
Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates
|
WO2024007016A2
(en)
|
2022-07-01 |
2024-01-04 |
Beckman Coulter, Inc. |
Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
|
WO2024015229A1
(en)
|
2022-07-15 |
2024-01-18 |
Sutro Biopharma, Inc. |
Protease/enzyme cleavable linker-payloads and protein conjugates
|
WO2024044780A1
(en)
|
2022-08-26 |
2024-02-29 |
Sutro Biopharma, Inc. |
Interleukin-18 variants and uses thereof
|
WO2024044327A1
(en)
|
2022-08-26 |
2024-02-29 |
Beckman Coulter, Inc. |
Dhnt monomers and polymer dyes with modified photophysical properties
|
WO2024098023A2
(en)
|
2022-11-04 |
2024-05-10 |
Sutro Biopharma, Inc. |
Interferon alpha polypeptides and conjugates
|
WO2024171078A1
(en)
|
2023-02-14 |
2024-08-22 |
H. Lundbeck A/S |
Treatment of opiod-induced pain
|